Dr. Brufsky on Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses the results of a phase II study that looked at the effect of prio...
Author: onclivetv
Added: 07/16/2014 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2014 Category: Cancer & Oncology Source Type: podcasts
Trastuzumab-containing regimens for metastatic breast cancer
Trastuzumab has been recognised as an effective therapy for women with HER2 positive breast cancer for several years, and a Cochrane Review on the effects for women with early stage disease was published in 2012. This was joined in June 2014 by a review of the drug’s effects for more advanced cancer. Sara Balduzzi from the University of Modena and Reggio Emilia in Italy describes these findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - June 13, 2014 Category: Journals (General) Authors: The Cochrane Collaboration Tags: Issue 4 to 6, April to June 2014 Source Type: podcasts
Trastuzumab containing regimens for metastatic breast cancer
Trastuzumab has been recognised as an effective therapy for women with HER2 positive breast cancer for several years, and a Cochrane Review on the effects for women with early stage disease was published in 2012. This was joined in June 2014 by a review of the drug’s effects for more advanced cancer. Sara Balduzzi from the University of Modena and Reggio Emilia in Italy describes these findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - June 1, 2014 Category: Journals (General) Authors: Cochrane Source Type: podcasts
TH3RESA Trial Update - Dr. Sunil Verma
Dr. Sunil Verma with updates from ECC 2013 on the study of trastuzumab emtansine in comparison with treatment of physician's choice in patients with her2-positive breast cancer who have received at le...
Author: oncologyeducation
Added: 10/07/2013 (Source: Oncology Tube)
Source: Oncology Tube - October 7, 2013 Category: Cancer & Oncology Source Type: podcasts
ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical ...
Author: feeds
Added: 09/04/2013 (Source: Oncology Tube)
Source: Oncology Tube - September 4, 2013 Category: Cancer & Oncology Source Type: podcasts
Trastuzumab Genetics
(Source: Mayo Clinic - Medical Edge Radio)
Source: Mayo Clinic - Medical Edge Radio - August 14, 2013 Category: Consumer Health Advice Authors: Mayo Clinic Source Type: podcasts
Listen to The Lancet: 18 July
Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - July 18, 2013 Category: Journals (General) Authors: The Lancet Source Type: podcasts
The Lancet: July 18, 2013
Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - July 18, 2013 Category: General Medicine Authors: The Lancet Source Type: podcasts
José Baselga,et al: Biomarker Analysis Identified Women Most Likely to Benefit From T-DM1
AACR 2013 Pressconference April 6: "Late Breaking Clinical Trials"
José Baselga,et al: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase 3 study of trastuzumab emt...
Author: feeds
Added: 04/11/2013 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2013 Category: Cancer & Oncology Source Type: podcasts
T-DM1 and the Dawn of Precision Medicine
Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - March 20, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
You Will Remember This Day
The FDA's approval of trastuzumab emtansine (T-DM1) for metastatic breast cancer, says Dr. Kathy Miller, marks a historic day in the fight against breast cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - February 21, 2013 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
The Lancet: January 29, 2010
Discussion of herceptin and chemotherapy for early advanced HER2+ breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - January 29, 2010 Category: General Medicine Authors: The Lancet Source Type: podcasts
